Literature DB >> 12875476

High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension.

Nieves Martell1, Matilde Rodriguez-Cerrillo, D E Grobbee, M Dolores López-Eady, Carmen Fernández-Pinilla, Mario Avila, Arturo Fernández-Cruz, Manuel Luque.   

Abstract

OBJECTIVE: To determine causes of treatment resistance in patients with refractory hypertension, and to estimate the prevalence of true resistant hypertension.
METHODS: We studied 50 consecutive patients referred with refractory hypertension after exclusion of hypokalemia and stenosis of the renal artery. Ambulatory blood pressure monitoring was performed in all patients to detect white-coat effect. The patients were hospitalized, antihypertensive drugs were withdrawn and a screening for secondary hypertension was performed. In addition, these patients, and a control group of essential hypertensives controlled with three antihypertensive drugs, underwent a OGTT with 75 g of glucose.
RESULTS: Primary normokalemic hyperaldosteronism was diagnosed in seven patients. Two patients had a pheochromocytoma and six had white-coat effect. The 35 remaining patients with true resistant hypertension shown significant differences in serum insulin and HOMA IR when compared with the control group.
CONCLUSIONS: These findings show that among normokalemic treatment-resistant hypertension, the presence of hyperaldosteronism and pheochromocytoma is quite high. Moreover, treatment resistance in hypertensive patients appears to be associated with insulin resistance.

Entities:  

Mesh:

Year:  2003        PMID: 12875476     DOI: 10.1080/08037050310009950

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  12 in total

Review 1.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 2.  Resistant or refractory hypertension: are they different?

Authors:  Rodrigo Modolo; Ana Paula de Faria; Aurélio Almeida; Heitor Moreno
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

Review 3.  Screening for pheochromocytomas and paragangliomas.

Authors:  Graeme Eisenhofer
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

4.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 5.  [Epidemiology and etiology of therapy-resistant hypertension].

Authors:  C Schirpenbach; M Reincke
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

Review 6.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

7.  Low Blood Pressure Is Associated With Greater Risk for Cardiovascular Events in Treated Adults With and Without Apparent Treatment-Resistant Hypertension.

Authors:  Brent M Egan; Bo Kai; C Shaun Wagner; Douglas O Fleming; Joseph H Henderson; Archie H Chandler; Angelo Sinopoli
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-10-21       Impact factor: 3.738

8.  Common secondary causes of resistant hypertension and rational for treatment.

Authors:  Charles Faselis; Michael Doumas; Vasilios Papademetriou
Journal:  Int J Hypertens       Date:  2011-03-02       Impact factor: 2.420

9.  Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.

Authors:  Beatriz de Rivas; Manuel Luque; Nieves Martell; Cristina Fernández; Arturo Fernández-Cruz
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-07       Impact factor: 3.738

Review 10.  Secondary hypertension: obesity and the metabolic syndrome.

Authors:  Gregory M Singer; John F Setaro
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.